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ABSTRACT
Vaccination induces immunostimulatory signals that are often accompanied 
by regulatory mechanisms such as IL-10, which control T-cell activation and 
inhibit vaccine-dependent antitumor therapeutic effect. Here we characterized IL-
10-producing cells in different tumor models treated with therapeutic vaccines. 
Although several cell subsets produced IL-10 irrespective of treatment, an early 
vaccine-dependent induction of IL-10 was detected in dendritic cells (DC). IL-10 
production defined a DC population characterized by a poorly mature phenotype, 
lower expression of T-cell stimulating molecules and upregulation of PD-L1. These 
IL-10+ DC showed impaired in vitro T-cell stimulatory capacity, which was rescued 
by incubation with IL-10R and PD-L1-inhibiting antibodies. In vivo IL-10 blockade 
during vaccination decreased the proportion of IL-10+ DC and improved their 
maturation, without modifying PD-L1 expression. Similarly, PD-L1 blockade did not 
affect IL- 10 expression. Interestingly, vaccination combined with simultaneous 
blockade of IL-10 and PD-L1 induced stronger immune responses, resulting in a higher 
therapeutic efficacy in tumor-bearing mice. These results show that vaccine-induced 
immunoregulatory IL- 10+ DC impair priming of antitumor immunity, suggesting that 
therapeutic vaccination protocols may benefit from combined targeting of inhibitory 
molecules expressed by this DC subset. 
INTRODUCTION
The tumor microenvironment is characterized by 
the presence of immunosuppressive molecules which 
induce inhibitory effects on antitumor immunity [1]. 
This microenvironment precludes correct activation of 
antigen-presenting cells (APC) responsible for priming 
T-cell responses [2] and the effector phase of tumor-
specific lymphocytes [3, 4]. Characterization of these 
immunosuppressive molecules has allowed the design of 
new therapies aimed at blocking their inhibitory functions, 
leading to activation of antitumor immunity and efficient 
clinical effects [5, 6]. Moreover, besides expression induced 
as a consequence of tumor growth, some therapies with 
an immunological component may also induce inhibitory 
elements as a negative feed-back mechanism [7]. Among 
them, vaccination induces not only T-cell-activating 
molecules, but also immunomodulatory mechanisms which 
regulate immune response activation [8–12]. 
IL-10 is a cytokine traditionally considered 
immunosuppressive due to its anti-inflammatory properties, 
mainly acting on APC by inhibiting expression of 
inflammatory cytokines and surface molecules associated 
with T-cell activation [13]. Different APC, including 
dendritic cells (DC), monocytes, macrophages and B-cells, 
as well as effector and regulatory T lymphocytes, produce 
IL- 10 [14]. However, besides inhibitory effects on APC 
with the concomitant down-regulation of T-cell activation, 
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IL-10 may also have a stimulatory role by enhancing 
effector functions on activated CD8 T-cells and by 
activating NK cells through inhibition of MHC molecules 
[15–17]. In cancer patients, elevated IL-10 levels are 
associated with a poorer prognostic [18–20], suggesting 
that its inhibition would have a beneficial effect [21]. We 
and others have shown that inhibition of IL-10 during 
vaccination enhances the magnitude of T-cell responses 
[22, 23]. Furthermore, during therapeutic vaccination of 
mice bearing IL-10-expressing tumors, we have recently 
reported the relevance of vaccine-induced IL-10, as 
opposed to that derived from the tumor, demonstrating 
its importance in the control of T-cell activation and 
in the therapeutic efficacy of vaccines [23]. Therefore, 
characterization of events associated with IL-10 production 
during vaccination may allow the design of better antitumor 
therapies. In the present work we identify cell populations 
producing IL-10 during therapeutic vaccination, analyzing 
their properties and potential association with other 
immunosuppressive pathways. We have observed that 
IL-10 is induced in DC with a less mature phenotype and 
decreased T-cell activation capacity. Moreover, they express 
additional immunomodulatory molecules like PD-L1, which 
contribute to their poor immunogenicity. Characterization 
of these molecules in DC sets the rationale to design new 
strategies combining therapeutic vaccines with blockade of 
relevant associated immunosuppressive molecules.
RESULTS
DC consistently produce IL-10 in an Imiquimod-
dependent manner
To characterize relevant IL-10-producing cells 
induced during therapeutic vaccination, we used IL-10 
reporter Vert-X mice [24]. Since IL-10 plays an inhibitory 
role even during vaccination of naive tumor-free mice [23], 
we started identifying IL-10+ cells in this setting. Mice 
were vaccinated with OVA+Imiquimod and compared to 
controls groups of untreated mice (UT) or mice vaccinated 
with OVA+poly(I:C), a vaccine in which IL-10 blockade 
did not provide any antitumor benefit [23]. In Imiquimod-
vaccinated mice, contrary to those in UT and poly(I:C) 
groups, a higher proportion of total splenic IL-10+ cells 
was detected two days after treatment (Figure 1A). Most 
populations specifically produced IL-10 after Imiquimod 
vaccination (Figure 1A and Supplementary Figure S1). 
However, DC clearly surpassed values observed for other 
cells. Regarding lymph nodes, DC and monocytes showed 
the highest proportions of Imiquimod-specific IL-10+ cells 
(Figure 1B). Vaccination of mice bearing B16-OVA tumors 
showed that Imiquimod induced again a general increase 
in the total splenic population, corresponding to higher 
values in all subsets (Figure 1C), a result corroborated 
when analyzing tumor-draining lymph nodes (Figure 1D). 
As in tumor-free mice, DC and monocytes showed the 
highest proportion of IL-10+ cells. High values were also 
observed in Tregs and NK cells, although this was not 
induced only by Imiquimod, since poly(I:C) also induced 
IL-10. Analysis of IL-10+ cells inside the tumor showed 
that most populations produced IL-10. However, IL-10 
production was not Imiquimod-specific, since clear IL-10 
production was detected in poly(I:C)-treated mice and even 
in some subsets in UT mice (as observed for Tregs), as we 
previously reported in tumor homogenates [23]. Of note, 
DC did not produce IL-10 in UT mice, and in vaccinated 
mice, probably due to adjuvant-induced migration, DC 
could not be detected in sufficient numbers to be analyzed 
(Supplementary Figure S2). 
Equivalent vaccination experiments in mice bearing 
TC-1 and E.G7-OVA tumors showed that although in most 
splenic cell populations the proportion of IL-10-producing 
cells increased after vaccination with Imiquimod, DC was 
the cell subset with the highest proportion of IL-10+ cells 
(Figures 1E–1F). These results show that several subsets, 
but mainly DC, consistently upregulate IL-10 production 
after vaccination in an Imiquimod-dependent manner.  
IL-10 with inhibitory effects on T-cell activation 
is induced at early time points after vaccination
To support that GFP expression observed in 
Vert-X mice indeed corresponded with IL-10, RT-PCR 
experiments measuring Il10 mRNA were carried out in 
C57BL/6 mice vaccinated with OVA+Imiquimod. To 
avoid missing IL-10 production at time points other than 
day 2, time-course experiments were carried out from 
day 1 to 7. We analyzed Il10 mRNA in purified splenic 
CD11c+ DC and CD4+ T-cells, representative of innate 
[25] and adaptive [22] cell populations producing IL-10. 
In DC IL-10 peaked at day 2, returning to basal levels at 
day 7, whereas in CD4+ T-cells, following a first peak at 
day 1 which decreased by day 4, a second, albeit weaker 
increase, was observed at day 7 (Figure 2A). 
The second IL-10 peak observed at day 7 in 
CD4+ cells prompted us to study IL-10 production by 
other cell populations at this time point, using tumor-
free mice, since equivalent results had been observed 
in lymphoid organs from tumor-free and tumor-bearing 
mice. Splenic CD4 Tregs maintained high Imiquimod-
independent IL-10 production, whereas in remaining 
subsets a marginal Imiquimod-specific induction was 
observed only in effector CD4 and in CD8 and NK cells 
(Figure 2B), according to PCR results of CD4 cells shown 
in Figure 2A. Indeed, additional analyses of intracellular 
IL-10 using splenic cells from vaccinated C57BL/6 mice 
confirmed that effector CD4 and to a lesser extent CD8 
T-cells, but not Tregs, specifically upregulated IL-10 in the 
Imiquimod group at day 7 (Figure 2C).
Since IL-10 blockade at day 0 enhanced T-cell 
responses [23], and two IL-10 peaks (an early peak mainly 
related to APC and a second peak related to T-cells) were 
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detected, we studied the functional relevance of the 
second peak by blocking IL-10 at day 4 after vaccination. 
Blockade at this time-point did not provide any 
beneficial effect, indeed, poorer responses were obtained 
(Figure 2D), suggesting that the enhancement of immune 
responses observed after IL-10 blockade at day 0 is mainly 
due to inhibition of IL-10 produced at early time-points 
after immunization, during the priming phase.
IL-10-producing DC have a different phenotypic 
and immunogenic profile and limit antitumor 
CD8 T-cell response activation
Due to the important proportion of IL-10+ APC 
induced by OVA+Imiquimod and considering the role 
that these cells play in T-cell priming (mainly for DC), 
phenotypic analyses comparing IL-10+ and IL-10-  cells 
were carried out after vaccination of naive and B16-
OVA tumor-bearing mice. IL-10+ DC had a less mature 
phenotype than their IL-10- counterparts, displaying a 
significantly lower expression of markers CD54, CD80 
and CD86 associated to cell adhesion and T-cell co-
stimulation (Figure 3A). However, in remaining APC 
populations, no differences were observed, except for 
higher CD80 values on IL-10+ B-cells (Supplementary 
Figure S3). This immature phenotype of IL-10+ DC 
was also observed in mice treated with other IL-10-
inducing vaccines. Indeed, EDA-OVA+MAC, a multiple 
adjuvant combination [26] whose antitumor effects 
also increased after IL-10 blockade [23] or OVA+LPS, 
[27] also induced IL-10+ DC with a similar phenotype 
(Supplementary Figure S4).
Figure 1: Identification of cell subsets producing IL-10 after therapeutic vaccination. Naive Vert-X mice (A–B), mice 
bearing 5 mm B16-OVA (C–D),  TC-1 (E) or E.G7-OVA tumors (F) (n = 8–11/group) were vaccinated with antigen (OVA in A–D and F or 
EDA-HPV-E7 in E) plus Imiquimod, antigen plus poly(I:C) or left untreated (UT). Two days later spleens or lymph nodes were obtained 
and the percentage of IL-10-producing cells was determined by flow cytometry in total cells and in the different subsets. Results correspond 
to the sum of 2–3 independent experiments.
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Additional features of IL-10+ DC were studied in 
purified splenic DC from Imiquimod-vaccinated mice. 
Regarding stimulatory cytokines, qPCR experiments 
showed that IL-10+ DC had lower levels of transcripts 
for Tnf and Il12b (encoding TNF-α and IL-12 p40, 
respectively). Interestingly, in the case of regulatory 
molecules, although no differences were observed in 
the expression of the tryptophan-catabolizing enzyme 
Ido1 (Figure 3B), higher surface PD-L1 expression 
was found in IL-10+ DC after immunization of naive 
mice or mice with different tumors (Figure 3C). These 
differences between IL-10+ and IL-10- DC in activating 
and inhibitory molecules led us to carry out transcriptomic 
studies. Differentially expressed genes were grouped in 
Gene Ontology terms and most over-represented terms 
corresponded to regulation of immune system process 
(p = 2.13 × 10−12), leukocyte activation (p = 7.19 × 10−9), 
immune response (p = 1.08 × 10−8) and cell activation 
(p = 9.97 × 10−8). Analyses of individual genes showed 
that IL-10+ DC had a profile characterized by the 
expression of inflammatory mediators, cytokines, 
chemokines and receptors attracting inflammatory cells, 
while simultaneously displaying lower levels of molecules 
associated to antigen processing/presentation and T-cell 
co-stimulation (Figure 3D), suggesting that although these 
cells may be activated, they are not properly endowed for 
T-cell priming.
Therefore, we next studied the capacity of these 
DC subsets to activate T-cell responses. In vitro antigen 
presentation assays showed that IL-10+ DC induced 
lower proliferation of OT-I CD8 T-cells than IL-10- DC. 
Interestingly, differences were clearer when using the 
whole OVA protein as antigen, compared with experiments 
using OVA(257–264) peptide, possibly related to defects 
in antigen processing/presentation machinery (Figure 4A). 
Most importantly, IL-10+ DC not only had a lower direct 
T-cell stimulatory capacity, but also actively inhibited 
T-cell stimulation induced by third party APC, reinforcing 
Figure 2: IL-10 with inhibitory effects on T-cell activation is induced at early time points after vaccination. (A) C57BL/6 
mice (n = 5/time-point) were vaccinated with OVA+Imiquimod and IL-10 mRNA was quantified by qPCR at different time-points in 
purified DC and CD4 cells. (B) Vert-X mice (n = 8/group) were vaccinated with OVA+Imiquimod, OVA+poly(I:C) or left untreated 
(UT) and one week later the percentage of splenic IL-10-producing cells was determined by flow cytometry. (C) C57BL/6 mice (n = 4) 
were vaccinated with OVA+Imiquimod or OVA+poly(I:C) and one week later splenocytes were stimulated with PMA/Ionomycin and 
intracellular IL-10 was determined by flow cytometry. (D) C57BL/6 mice (n = 4) were vaccinated with OVA+Imiquimod with or without 
blockade of IL-10 at day four after vaccination. At day 7, OVA-specific responses were determined by ELISPOT. Results are representative 
of 2 independent experiments.
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their immunosuppressive role (Figure 4B). To test in vivo 
the functional relevance of DC-derived IL-10, vaccination 
experiments were carried out in IL-10fl/fl x CD11c-Cre+ 
mice, selectively lacking IL-10 in DC, or in IL-10fl/fl x 
LysM-Cre+ mice, lacking IL-10 mainly in myeloid cells 
(monocytes/macrophages/granulocytes). Immunization 
with OVA+Imiquimod induced stronger T-cell responses 
in mice lacking IL-10 in DC than in their littermates with 
IL-10-proficient DC. However, no statistically significant 
differences were observed in mice lacking IL-10 in 
myeloid cells (Figure 4C). More importantly, similar to the 
results obtained when combining therapeutic vaccination 
plus systemic IL- 10 blockade [23], treatment of E.G7-OVA 
tumor-bearing mice with the OVA+Imiquimod vaccine 
had a stronger antitumor effect in mice lacking IL- 10 
in DC than in those having competent DC (Figure 4D). 
Indeed, whereas only 16% of mice with IL-10+ DC 
rejected their tumor, 67.5% of tumors were rejected in 
mice lacking IL- 10 in DC. Overall, these results stress 
the importance of IL-10+ DC which, besides producing 
this immunosuppressive factor, are in a less-immunogenic 
condition, both at the phenotypical and functional 
level, leading thus to poorer CD8 T-cell priming during 
vaccination and restraining treatment efficacy.
Figure 3: IL-10-producing DC have a different phenotypic and immunogenic profile. (A) Maturation associated markers 
were determined in IL-10- and IL-10+ DC from Vert-X mice (n = 4) with or without B16-OVA tumors two days after vaccination with 
OVA+Imiquimod. Left column corresponds to representative results of CD54, CD80 and CD86 molecules in DC from a vaccinated naive 
mouse, whereas middle and right columns show data corresponding to same markers in grouped naive and B16-OVA-vaccinated animals. 
(B) mRNA expression of several genes was analyzed by qPCR in purified  IL-10– and IL-10+ DC from Vert-X mice (n = 8) vaccinated as 
in A. (C) PD-L1 expression was measured by flow cytometry in DC from naive and B16-OVA and E.G7-OVA tumor-bearing mice (n = 4). 
Results are representative of 2–3 independent experiments. (D) Gene expression was analyzed in DC subsets. Results are shown as fold-
change (FC), with upregulation in IL-10+ DC (gray bars) or in IL-10- DC (white bars).
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In vivo IL-10 blockade rescues mature 
phenotype of DC
We described that IL-10 blockade during therapeutic 
vaccination increased T-cell responses, associated with a 
more mature DC phenotype and enhanced functions, such 
as IL-12 production [23]. Thus, to dissect this rescuing effect 
of IL-10 blockade, IL-10-producing cells were analyzed in 
Vert-X mice vaccinated with OVA+Imiquimod, subjected or 
not to IL-10 blockade. A trend leading to a lower proportion 
of IL-10+ cells was observed in whole splenic cells after IL-
10 blockade, which was statistically evident when specifically 
examining DC and B-cells. However, no differences were 
found in monocytes or macrophages (Figure 5A). Next, 
the effect of IL-10 blockade on DC phenotype was studied, 
according to their ability to produce IL-10. IL-10 blockade 
did not have any effect on IL-10- DC phenotype (data not 
shown). Interestingly, increased expression levels of co-
stimulatory molecules were found in IL-10+ DC from mice 
treated with blocking antibodies (Figure 5B). These results 
indicate that both mechanisms, lower proportion of IL-10+ 
DC and increased maturation, contribute to promote an 
overall higher number of mature DC after IL-10 blockade.
Imiquimod-based vaccination induces DC 
with dual IL-10/PD-L1 expression whose 
simultaneous blockade increases antitumor 
efficacy of therapeutic vaccines
Despite their less mature phenotype, IL-10+ DC 
displayed higher levels of PD-L1 (Figure 3C), a molecule 
associated with TLR-activated DC [9, 28–30] which is 
involved in tumor immunosuppression [31]. This PD-
L1 up-regulation was also observed in other IL-10+ APC 
(Supplementary Figure S5). We were thus interested 
in studying the association between IL-10 production 
and PD-L1 expression in different vaccination models. 
Examining whole splenocytes in B16-OVA-tumor-bearing 
mice, both poly(I:C)- and Imiquimod-based vaccines 
enhanced the proportion of PD-L1 expressing cells. 
However, Imiquimod, besides inducing IL-10, led to the 
highest percentages of PD-L1+ cells, a result also observed 
after vaccination of naive tumor-free mice (Supplementary 
Figure S6). When specifically considering DC, although 
most cells (> 95%) were PD-L1+ irrespective of the 
vaccine (data not shown), clear differences were observed 
when analyzing the intensity of PD-L1 expression. While 
Figure 4: IL-10-producing DC have a poorer T-cell stimulatory capacity and limit the efficacy of anti-tumor therapeutic 
vaccination. (A) Purified IL-10- and IL-10+ DC from Vert-X mice (n = 8–10) were pulsed with peptide OVA(257–264) or OVA protein 
and used to stimulate OT-I CD8 T-cells. T-cell proliferation was determined three days later. (B) Total OT-I splenocytes (OT-I Spl) were 
pulsed or not with peptide OVA(257–264) and after washing the peptide, some wells additionally received IL-10- or IL-10+ DC and T cell 
proliferation was measured as above.  (C) IL-10fl/fl x CD11cCre+ and IL-10fl/fl x CD11cCre- mice (n = 4–5/group) or IL-10fl/fl x LysMCre+ 
and IL-10fl/fl x LysMCre- mice (n = 6/group) were immunized with OVA+Imiquimod and one week later OVA-specific responses were 
determined by ELISPOT. Results are representative of 2–3 independent experiments. (D) IL-10fl/fl x CD11cCre+ and IL-10fl/fl x CD11cCre- 
mice (n = 6–8/group)  bearing 5 mm E.G7-OVA tumors were treated with three weekly vaccination cycles with OVA + Imiquimod and 
tumor volume was monitored.
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the poly(I:C)-based vaccine induced some increase 
regarding the UT group, Imiquimod-vaccinated mice 
expressed the highest PD-L1 levels, after vaccination of 
both tumor-bearing and naive mice (Figure 6A). 
Enhanced PD-L1 levels on IL-10+ cells and 
data concerning interactions in the expression of these 
molecules [32–34] prompted us to analyze a potential 
association in their mutual expression. Thus, Vert-X 
mice were vaccinated with OVA+Imiquimod, with or 
without blockade of these molecules. IL-10 blockade did 
not modify PD-L1 expression, neither in IL-10+ nor in 
IL-10− cells. This was observed when studying the whole 
splenic cell populations (Supplementary Figure S7A) 
and separately in DC (Figure 6B), B-cells, monocytes 
and macrophages (data not shown). Similarly, PD-L1 
blockade did not modify the proportion of vaccine-
induced IL-10+ cells (Figure 6C and Supplementary 
Figure S7B). To test the functional relevance of these 
immunosuppressive factors in IL-10+ DC, we repeated 
in vitro antigen presentation assays combined with 
blocking antibodies. While PD-L1 blockade only induced 
a minimal increase in T-cell stimulation by IL-10- DC, both 
IL-10R and PD-L1 blockade clearly led to enhanced T-cell 
responses induced by IL-10+ DC (Figure 6D), suggesting 
that these immunosuppressive factors play important and 
independent roles as inhibitory molecules in IL-10+ DC in 
the vaccination setting. Although PD-1 expression was not 
detected in CD8 T cells in lymphoid organs of naive mice 
one week after vaccination (data not shown) presumably 
due to the low frequency of Ag-specific cells induced by 
the vaccine, PD-1 was observed in tumor bearing mice, 
whose OVA(257–264) Tetramer+ frequencies ranged 
between 5 and 8%. Indeed, 20% of these Tetramer+ cells 
expressed PD-1 in tumor-draining lymph nodes whereas 
these values increased to 80% in tumor infiltrating T 
lymphocytes (Supplementary Figure S8), supporting that 
in vivo, similarly to IL-10 blockade, inhibition of PD-1/
PD-L1 axis would enhance vaccine-induced antitumor T 
cell responses. Accordingly, the rescuing effect observed 
after in vitro blockade was translated in vivo in vaccination 
experiments with dual blockade. Both IL-10R and PD-
L1 blocking antibodies enhanced vaccine-induced T-cell 
responses, which were clearly increased after combined 
administration (Figure 6E). 
Since the combination of the vaccine with the 
simultaneous blockade of IL-10R and PD-L1 gave 
the best results in immunization experiments, we tested 
the antitumor therapeutic relevance of this strategy in mice 
bearing B16-OVA tumors. We chose anti-PD-1 antibodies 
to inhibit the PD-1/PD-L1 pathway, similarly to initially 
approved therapies against this axis. Although individual 
therapies based on vaccination or inhibitory antibodies 
had some effect on tumor growth, combination therapy 
potently inhibited tumor growth (Figure 6F).
Figure 5: In vivo IL-10 blockade rescues mature phenotype of DC. (A) Vert-X mice (n = 4/group) were vaccinated with 
OVA+Imiquimod with or without IL-10 blockade and 2 days later the proportion of total splenic cells and DC, B-cells, monocytes and 
macrophages producing IL-10 was determined by flow cytometry. (B) Phenotype of IL-10+ DC from vaccinated mice was also analyzed in 
these groups. Results are representative of 2–3 independent experiments.
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Figure 6: Blockade of vaccination-induced IL-10/PD-L1 in DC potentiates T-cell responses and increases antitumor 
therapeutic efficacy. (A) Naive or B16-OVA tumor-bearing Vert-X mice (n = 4/group) were vaccinated with OVA+Imiquimod, 
OVA+poly(I:C) or left untreated. Two days later PD-L1 expression was determined in DC. (B) Vert-X mice (n = 4/group) were vaccinated 
with OVA+Imiquimod with or without IL-10 blockade and PD-L1 expression was determined two days later in IL-10- and IL-10+ DC. 
(C) Vert-X mice (n = 4/group) were vaccinated with OVA+Imiquimod with or without PD-L1 blockade and the proportion of IL-10+ DC 
was determined two days later. (D) IL-10- and IL-10+ DC obtained from OVA+Imiquimod-vaccinated mice were used to stimulate OT-I 
CD8 T-cells in the presence of OVA(257–264) plus control or IL-10R- or PD-L1-blocking antibodies. T-cell proliferation was determined 
three days later. (E) C57BL/6 mice (n = 4/group) were vaccinated with OVA+Imiquimod together with control or IL-10R- or PD-L1-
blocking antibodies and one week later OVA(257–264)-specific responses were determined by ELISPOT. (F) C57BL/6 mice (n = 7–8/
group) bearing 5 mm B16-OVA tumors were treated with three weekly vaccination cycles with OVA+Imiquimod with or without IL-10R/
PD-1-blocking antibodies and tumor volume was monitored. Results are representative of 2–3 independent experiments.
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DISCUSSION
Activation of immunity is accompanied by 
concomitant triggering of self-regulatory mechanisms 
to avoid excessive responses with harmful effects. 
However, in cancer, either during tumor progression or as 
a consequence of therapies, some control mechanisms are 
over-expressed and preclude correct induction of antitumor 
responses. Here we have analyzed the role of IL-10, a 
cytokine with controversial effects on tumor immunity 
[16], reported as detrimental for T-cell priming during 
therapeutic vaccination [23, 25]. We have observed in 
different tumor models that, although several cell subsets 
may produce IL-10 upon Imiquimod-based vaccination, 
APC (namely DC) consistently produce IL-10 at early 
time-points. Tregs or NK cells may also produce important 
amounts of IL-10; however, this source does not seem to 
be relevant, since it occurs in the absence of vaccination 
or with vaccines where IL-10 inhibition is not beneficial. 
Previous studies in Imiquimod-vaccinated mice have 
shown the importance of IL-10. Although the relevant 
IL-10 source was not identified, Tregs and B-cells were 
discarded [35], in agreement with our results highlighting 
DC. Immunomodulatory IL-10 produced by DC at early 
time points [25] is congruent with the role these cells play 
at initial stages of T-cell activation, whereas production 
at later time points (e.g., day 7) is associated with Tr1-
derived IL-10, as reported in a prolonged Imiquimod-based 
therapy model [22]. Several issues stress the relevance of 
IL-10+ DC. First, there is a phenotypical and functional 
impairment specifically associated to DC expressing this 
cytokine. Indeed, IL-10 production is associated not only 
with a less mature DC phenotype (not observed in other 
APC subsets), but also with a functional impairment in 
T-cell priming, shown as a poorer stimulatory capacity 
and as a direct suppressive capacity. Second, the enhanced 
antitumor immunity resulting from IL-10 blockade during 
vaccination is associated with effects at the DC level, 
both by decreasing the number of IL-10+ DC and by 
upregulating maturation-associated molecules in these 
cells. Finally, selective depletion of DC-derived IL-10, 
but not in other APC, leads to improved in vivo responses 
and antitumor effect. It is interesting to note that not all 
adjuvants used have shown the same capacity to in vivo 
induce IL-10-producing DC. Indeed, whereas these cells 
were not detected in mice immunized with poly(I:C)-
based vaccines, they were clearly observed when using 
Imiquimod, LPS or a multiple adjuvant combination 
(MAC). We previously reported the capacity of  MyD88-
depending adjuvants (Imiquimod, CpG oligonucleotides) 
to induce in vitro IL-10 production by DC, as opposed 
to those independent on MyD88 (poly(I:C), anti-CD40 
agonistic antibodies) [23]. Interestingly, it has been 
reported that IL-10 produced by DC dampens MyD88-
dependent, but not MyD88-independent signaling [36], 
suggesting that signalling through receptors which depend 
on this pathway may be associated to the inhibitory effect 
that we observe in DC.
Immunoregulatory IL-10+ DC have been recently 
described in murine models of sustained inflammation and 
immunosuppression like chronic infections, characterized 
by their poor stimulatory capacity associated with increased 
expression of negative regulatory factors [37, 38]. However, 
as opposed to IL-10+ DC found in our vaccination setting, 
those IL-10+ DC expressed higher CD80 and CD86 levels 
[37]. Vaccine-associated acute inflammation versus chronic 
inflammation corresponding to those settings might explain 
these differences. Interestingly, in humans, individuals treated 
with Imiquimod show an early peak of IL-10 at day 2 [39]. 
Moreover, human DC grown in an IL-10 rich environment 
display an immature phenotype together with increased 
IL-10 and PD-L1 expression [40], resembling our results. 
Among immunoregulatory molecules over-
expressed in IL-10+ DC, PD-L1 is of special interest 
due to its prominent role in immunoregulation and 
the availability of new clinical treatments targeting 
this pathway [41, 42]. Although DC activation leads to 
PD- L1 upregulation [9, 28–30], our results show that 
not all vaccine adjuvants promote PD-L1 expression to 
the same levels. Thus, whereas poly(I:C) upregulates 
PD- L1 to some extent, Imiquimod induces the highest 
PD-L1 levels, more evidently in IL-10+ DC, reinforcing 
the immunoregulatory role of this subset. PD-L1 and 
IL- 10 have been shown to inhibit anti-tumor responses 
in different tumors [18–20, 43]. Although their expression 
can be mutually regulated [32–34], in our vaccination 
setting IL-10 and PD-L1 do not exert reciprocal effects. 
Prolonged expression of these molecules in established 
tumors, contrary to the short-time induction we see 
during vaccination, may explain discrepancies observed 
in the regulation of their mutual expression, resulting 
in different pathways that induce and control their 
presence. Interestingly, this expression confers upon 
them separate inhibitory mechanisms and their blockade 
independently rescues antigen-presenting properties of 
IL-10+ DC, suggesting that they could be considered as 
separate targets in strategies aimed at enhancing T-cell 
responses by potentiating DC activity. Accordingly, their 
combined blockade during vaccination induces stronger 
antitumor responses, resulting in a higher therapeutic 
efficacy. PD-1/PD-L1 blocking therapies are currently 
being used with interesting results preferentially in 
PD-L1+ tumors. However, besides tumor cells, infiltrating 
immune cells may also express inhibitory PD-L1 [43]. 
Our results add a new element to this setting, suggesting 
a superior beneficial effect of those combination therapies 
which include vaccines and these checkpoint inhibitors. 
It has been recently reported that in melanoma patients, 
NY-ESO-1-specific CD8 T-cells expressing high PD-1 
levels upregulate IL-10R upon antigen recognition, being 
inhibited thus by these two immunosuppressive pathways 
[44]. Interestingly, simultaneous blockade of these targets 
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promoted expansion and antitumor functions of these 
cells, resembling our in vivo vaccination results. These 
data suggest that Imiquimod-based vaccination clinical 
trials [45] could benefit from simultaneous blockade of 
IL-10 and PD1/PD-L1. 
Finally, the concept of antitumor therapeutic 
vaccine is currently being expanded from the classical 
antigen+adjuvant administration to therapies that release 
tumor antigens associated to immunogenic cell death 
[46]. Some endogenous alarm molecules induced by 
conventional therapies (e.g. HMGB1) signal in DC 
through TLR4 [47], a pathway known to induce IL- 10 
[27]. Thus, it is tempting to speculate that some DC 
stimulated through this pathway would resemble and 
acquire the properties of immunoregulatory DC described 
in the present work, suggesting that ongoing clinical trials 
combining immunogenic cell death-inducing agents, such as 
doxorubicin, with anti-PD-1 antibodies (e.g. NCT02181738, 
NCT02499367, NCT02622074, NCT02331251; clinicaltrials.
gov) might also benefit from IL-10 blockade.
In summary, we have described an IL-10+ DC subset 
induced by vaccination, with an immature phenotype and 
poor stimulatory capacity, associated with inhibitory 
molecules such as PD-L1. Combination of vaccines 
with blockade of these or additional immunosuppressive 
targets expressed by these cells may yield more efficient 
immunotherapeutic protocols.
MATERIALS AND METHODS
Antigens
Peptide OVA(257-264) > 95% pure (NeoMPS) and 
immunogens  OVA (low endotoxin; Hyglos) and EDA-
HPVE7 have been previously described [23]. 
Mice
Vert-X (B6(Cg)-Il10tm1.1Karp/J), OT-I (C57BL/6-
Tg(TcraTcrb)1100Mjb/J) and LysMCre (B6.129P2-
Lyz2tm1(cre)Ifo/J) mice were obtained from Jackson. IL- 10fl/ fl 
(Il10tm1Roer) and CD11cCre (Tg(Itgax-cre)1-1Reiz) 
mice were kind gifts from Drs. A. Roers (Institute for 
Immunology, Dresden; Germany) and D. Sancho (CNIC, 
Madrid; Spain), respectively. Female C57BL/6 were 
from Harlan (Barcelona, Spain). They were maintained 
in pathogen-free conditions and treated according to 
guidelines of our institution, after study approval by the 
review committee.
Cell lines
B16-OVA tumor cells (obtained from Dr. G. Kroemer; 
Paris, France), E.G7-OVA (from ATCC) and TC-1-P3(A15) 
cells, (obtained from Dr. T.-C. Wu; Baltimore, USA) were 
grown as described [23]. Cell stocks were created upon 
cell line receipt and early passages were used for tumor 
experiments. They were routinely tested for mycoplasma. 
Re-authentification of cells was not performed since receipt.
Immunization of mice
Mice were injected with B16-OVA cells (105, 
intradermally), TC-1-P3(A15) (105, subcutaneously) or 
E.G7-OVA (5 × 105, subcutaneously) and when the tumor 
diameter reached 4–5 mm, they received intratumoral 
administration of OVA protein (0.5 mg/mouse) or EDA-
HPVE7 immunogen [23] (2 nanomoles) combined with 
Imiquimod cream (Meda-Aldara™; topical application; 
2.5 mg/mouse),  poly(I:C) (Amersham; 50 μg/mouse; 
intratumor) or left untreated. Tumor-free mice received 
similar immunizations by subcutaneous route. At different 
time-points they were sacrificed and splenocytes, lymph 
node cells or tumor-infiltrating cells were obtained for 
characterization. Additionally, they received i.p. injection 
of anti-IL-10R (500 μg), anti-PD-L1 (200 μg) or the 
corresponding isotype control antibodies (all from BioXcell).
Tumor treatment experiments
Mice bearing 4–5 mm B16-OVA or E.G7-OVA 
tumors received 3 weekly cycles of OVA (intratumor; 
0.5 mg/mouse) combined with Imiquimod at day 0 as 
described [23]. Some groups received anti-IL-10R, anti-
PD-1 or isotype antibodies as above at days 0, 7 and 
14. Untreated mice bearing similar tumors were used as 
positive controls of tumor growth. Tumor volume was 
calculated using the formula: V= (length × width2)/2. Mice 
were killed when tumor diameter reached 17 mm.
ELISPOT
T-cells producing IFN-γ were determined 
by ELISPOT (BD-Biosciences) as described [23]. 
Splenocytes (5 × 105/well) were stimulated with peptide 
OVA(257–264) for 24 h and the number of spot-forming 
cells was enumerated with an automated counter.
Flow cytometry
Lymphoid organs and tumors were obtained after 
vaccination, treated with collagenase and DNAse for 
15 minutes and homogenized. Cells were incubated for 
10 min with Fc Block™ (BD-Biosciences) and stained 
with specific antibodies. Analysis of cells producing IL-
10 in Vert-X mice (GFP+ cells) was performed by using 
antibodies CD11c-BV570, F4/80-Pacific Blue, CD11b-
APC, Ly6C-PE-Cy5 (all from Biolegend) and Ly6G-
PE-Cy7 (BD-Biosciences), to define DC, monocytes and 
macrophages. CD3-PE-Cy5 (AbD serotec), NKp46-PE 
(BD-Biosciences), CD19-APC (BD-Biosciences), CD8 
BV421 (Biolegend), CD4-BV570 (Biolegend) and CD25-PE-
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Cy7 (TONBO Biosciences) were used to define lymphocytic 
subsets (Supplementary Figure S1). For intracellular IL-10 
detection in C57BL/6 mice, splenocytes were stimulated 4 
h with PMA/Ionomycin in the presence of GolgiStop and 
GolgiPlug (BD-Biosciences), surface stained with CD3-
PE-Cy5, CD8-BV421, CD4-BV570 and CD25-PE-Cy7 
antibodies and intracellular stained with anti-IL10-PE 
(Biolegend). For APC characterization studies, splenocytes 
were stained in different panels combining CD11c-BV570, 
F4/80-BV421, CD11b-PE (BD-Biosciences), Ly6C-PE-Cy5, 
Ly6G-PE-Cy7, CD19-APC-Cy7 (Biolegend), CD80-BV421 
(BD-Biosciences), CD54-APC (Biolegend), CD86-PE-Cy5 
(Biolegend) or CD86-BV510 (Biolegend), I-Ab-PE (BD-
Biosciences) and PD-L1-PE (BD-Biosciences) antibodies. 
PD-1 expression on CD8 T cells was determined by staining 
cells obtained from spleen, lymph nodes or tumors with CD8-
Pacific Blue (AbD Serotec), OVA(257–264)-Tetramer-APC 
(MBL) and PD-1-FITC (Miltenyi). Samples were acquired 
in a FACSCantoII flow cytometer (Becton Dickinson) and 
analyzed using Flowjo software (Tree Star Inc).
Cell purification 
For IL-10 RT-PCR time-course experiments in C57BL/6 
mice, animals were vaccinated with OVA+Imiquimod and 
anti-CD11c-conjugated magnetic beads were used to purify 
splenic DC, whereas CD4 T-cells were purified by negative 
selection (Miltenyi; Germany). Splenic IL-10+ and IL-10- DC 
from Vert-X mice vaccinated with OVA+Imiquimod used 
for PCR studies, microarrays and antigen presenting assays 
were purified by using anti-CD11c-conjugated magnetic 
beads followed by staining with CD11c-APC antibodies (BD-
Biosciences) and separation with a FACSAria flow cytometer 
according to their expression of IL-10 (GFP). 
Real-time PCR
Purified DC were resuspended and RNA extracted 
(Simply RNA Kit; Promega). Real-time PCR was 
performed as described [26], using primers GGACAACA 
TACTGCTAACCG and AATCACTCTTCACCTGCTCC 
(IL-10), AGATGAAGGAGACAGAGGAG and GGAAA 
AAGCCAACCAAGCAG (IL-12 p40), CTTCCAGAACT 
CCAGGCGGT and GGTTTGCTCGACGTGGGC (TNFα),
CCTTGAAGACCACCACATAG and AGCACCTTTCGAA
CATCGTC (IDO) and CGCGTCCACCCGCGAG and CCTG
GTGCCTAGGGCG (β-actin). Results were normalized according 
to b-actin. The amount of each transcript was expressed by the 
formula: 2ΔCt (ΔCt = Ct(β-actin)-Ct(gene)).
Microarrays
RNA samples from IL-10+ and IL-10- DC were 
labeled, hybridized and scanned according to standard 
protocols (Affymetrix, Santa Clara, CA, USA). Briefly, 
2 ng of RNA were processed using the Affymetrix 
GeneChip® WT Pico Kit.  Hybridization cocktails were 
hybridized to the GeneChip® Mouse Gene 2.0 ST Arrays, 
incubated at 45°C for 16 hours, washed and stained on an 
GeneChip® Fluidics 450 workstation (Affymetrix). They 
were scanned using the Affymetrix GeneChip® Scanner 
3000 7G. Data normalization was performed with RMA 
[48]. After quality assessment using R/Bioconductor [49], a 
filtering process was carried out to eliminate low expression 
probe sets. Applying the criterion of an expression value 
> 4 in both samples, 30436 probe sets were selected for 
analysis. Genes were selected as differentially expressed 
using a fold-change cut off > 1 and functional enrichment 
analysis of Gene Ontology categories was performed using 
the hypergeometric distribution in R. Data are publicly 
available in GEO database (accession number GSE84980).
Proliferation assays
In direct antigen presentation assays purified DC (6 × 
103) and OT-I CD8 T-cells (1.8 × 104) were co-cultured 
(n = 4 wells/condition) with or without peptide OVA(257–
264) (1 μg/ml) or OVA protein (10 μg/ml). In some cases, 
antibodies against IL-10R, PD-L1 or isotype control 
(10 μg/ml) were also added. Two days later 0.5 μCi of H3-
thymidine were added and cell proliferation was counted 
after overnight incubation. For suppression assays, 105 OT-I 
total splenocytes were pulsed for 2 h with a suboptimal dose 
of OVA(257–264) (1 ng/ml), then peptide was extensively 
washed, 1.5 x 104 unpulsed IL-10+ or IL-10- DC were added 
and T cell proliferation was measured as above. 
Statistical analysis
Tumor growth was fitted to a third order polynomial 
and compared with the Extra sum-of-squares F test. 
Immune responses were analyzed using nonparametric 
Kruskal-Wallis and Mann-Whitney U tests. p<0.05 was 
taken to represent statistical significance.
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